COVID-19: General Guidance for Vaccinators

Four people showing their arm with band-aid after vaccination

The Wisconsin Department of Health Services (DHS) has issued the "Statewide COVID-19 Vaccination Standing Order for the 2025–26 Respiratory Virus Season." This will ensure the 2025-26 COVID-19 vaccine is available to all Wisconsinites 6 months and older who want the vaccine, in alignment with recommendations from the American Academy of Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Family Physicians (AAFP).

Vaccinators are the front line of defense to stopping the spread of COVID-19. This webpage has critical guidance and resources about COVID-19 vaccines for people ages 6 months and older, covering:

  • Administration
  • Clinical considerations

Useful tools and resources

Vaccination clinical guidance

The nation’s leading medical organizations recommend that everyone 6 months and older receive the 2025–2026 COVID-19 vaccine. This is especially important for:

  • People 65 and older;
  • Those who are at risk for severe complications from COVID-19 especially infants and children under age 2, those who are pregnant, planning to become pregnant, or who have recently given birth; and children, adolescents, and adults with underlying health conditions;
  • Those who have never received a COVID-19 vaccine.

Wisconsin Immunization Registry verification

Vaccinators are encouraged to check the Wisconsin Immunization Registry (WIR) before administering a vaccine to verify that individuals are receiving the correct vaccine based on the specific vaccination schedule for their age group and/or medical history.

Resources

Observation period

Individuals receiving any vaccine, including COVID-19, need to be monitored for allergic reactions for 15-30 minutes after vaccination. Non-reactions to previous vaccinations are not a guarantee that a reaction will not occur. When administering doses, please make sure people wait before they leave your site.

COVID-19, influenza, and other vaccines may be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as co-administration within 14 days.

Giving all vaccines for which an individual is eligible at the same visit is considered a best practice as it increases the probability that individual will be up to date on recommended vaccines. It also is an important part of immunization practice, especially if a health care provider is uncertain that a patient will return for additional doses of vaccine.

Reference CDC's clinical considerations for more details.

You can also print out Immunize.org's job aid, How to Administer Multiple Intramuscular Vaccines to Adults During One Visit (PDF).

Vaccinators need to ensure that emergency equipment is available regardless of the vaccine being administered. This includes epinephrine auto-injectors or epinephrine.

According to the CDC, state laws establish vaccination requirements for school-aged children. In Wisconsin, the age of majority is 18 years of age, unless emancipated. Therefore, all unemancipated individuals under 18 years of age require parent or guardian consent to receive the COVID-19 vaccine.

In Wisconsin, vaccinators can accept written or verbal (such as via telephone) consent to administer the COVID-19 vaccine from a minor’s legal parent or guardian who cannot be present at the time of vaccination. Vaccinators are not required to accept written or verbal consent but are permitted to accept these forms of consent should they choose to do so.

DHS does not have a sample written consent form for vaccinators to use. Vaccinators are encouraged to work with their own legal counsel regarding methods of consent for vaccinating minors in their clinic.

People who are pregnant or recently pregnant should take steps to protect themselves from getting sick with COVID-19. 

The American College of Obstetricians and Gynecologists (ACOG) strongly recommends that pregnant individuals be vaccinated against COVID-19.

Increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination, particularly in adolescents and young adults.

The nation’s leading medical organizations continue to recommend COVID-19 vaccination for everyone 6 months and older, given the risk of COVID-19 illness and related, possibly severe complications, such as long-term health problems, hospitalization, and even death.

Vaccination is important because the risk of myocarditis or pericarditis associated with SARS-CoV-2 infection is greater than the risk of myocarditis or pericarditis occurring after receipt of an mRNA COVID-19 vaccine in adolescents and adults. However, people who develop myocarditis or pericarditis after a dose of an mRNA COVID-19 vaccine generally should not receive a subsequent dose of any COVID-19 vaccine. For more information see COVID-19 vaccination and myocarditis and pericarditis.

Health care providers should consider myocarditis in an evaluation of chest pain after vaccination and report all cases to the Vaccine Adverse Event Reporting System (VAERS) in a timely manner.

The Vaccine Adverse Event Reporting System (VAERS) is a national vaccine safety surveillance program that has been used to detect possible safety issues with vaccines for many decades. Anyone can, but medical providers must, report adverse events (possible side effects or health problems) that occur after vaccination using VAERS.

Health care personnel or health departments in the U.S. can request a consultation from the Clinical Immunization Safety Assessment (CISA) COVIDVax project for a complex COVID-19 vaccine safety question about an individual patient residing in the U.S. not readily addressed by CDC guidance.

Request a consultation from CISA by:

 Calling 800-CDC-INFO (800-232-4636)

For more information about vaccine safety, review What Every Clinician Should Know about COVID-19 Vaccine Safety.

Email us at DHSImmProgram@dhs.wisconsin.gov if you have more questions about vaccine safety or reporting adverse events.

Product-specific resources

Glossary

 
Last revised September 16, 2025